Nicotinic acid (niacin) lowers LDL cholesterol and triglycerides, and raises HDL (good) cholesterol. These medicines should only be used under a doctor's supervision.
Microsomal Triglyceride Transfer Protein Inhibitors
Approved in December 2012, lomitapide (Juxtapid™) is the first and only medication in this class. It is approved for a specific genetic high cholesterol disorder known as homozygous familial hypercholesterolemia (HoFH).
This medication may be prescribed and dispensed only by healthcare providers and pharmacies that have been specially certified to do so, due to the potentially serious risks associated with its use. In particular, lomitapide can cause serious liver problems.
Approved in January 2013, mipomersen (Kynamro™) is the first and only medication in this class. It is approved for a specific genetic high cholesterol disorder known as homozygous familial hypercholesterolemia (HoFH). It is given as an injection just under the skin (a subcutaneous injection) once a week and is intended for use in combination with other cholesterol medications. Like many other cholesterol medications, mipomersen can cause serious liver problems, and careful monitoring of the liver (using routine blood tests) is recommended.
Cholesterol is not a bad thing -- it serves an important purpose in keeping the body healthy. Unfortunately, some people who have high cholesterol choose to ignore it because there are no obvious symptoms. Having high levels of cholesterol for a long time can greatly increase your risk of serious medical problems, like heart disease, stroke, atherosclerosis, and other heart and blood vessel problems.
Even though lowering cholesterol can be a challenge, commitment and care from you and your healthcare providers can make a difference. Whatever the approach you take to treating cholesterol, making a lifelong commitment to lower your high cholesterol is a worthy goal.